Bridge chooses Catalent for opioid addiction treatment manufacture

From BioPortfolio: Catalent completes clinical production of opioid addiction therapeutic developed by Bridge using Zydis technology and gets exclusive license ahead of regulatory…

Read the full article here

Related Articles